Supernus Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $33.02
- Today's High:
- $33.71
- Open Price:
- $33.35
- 52W Low:
- $25.8
- 52W High:
- $42.09
- Prev. Close:
- $32.96
- Volume:
- 614100
Company Statistics
- Market Cap.:
- $1.83 billion
- Book Value:
- 16.746
- Revenue TTM:
- $668.50 million
- Operating Margin TTM:
- 6.96%
- Gross Profit TTM:
- $580.02 million
- Profit Margin:
- 7.79%
- Return on Assets TTM:
- 1.69%
- Return on Equity TTM:
- 5.98%
Company Profile
Supernus Pharmaceuticals Inc had its IPO on 2012-05-01 under the ticker symbol SUPN.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Supernus Pharmaceuticals Inc has a staff strength of 612 employees.
Stock update
Shares of Supernus Pharmaceuticals Inc opened at $33.35 at the start of the last trading session i.e. 2023-06-03.
The stocks traded within a range of $33.02 - $33.71, and closed at $33.53.
This is a +1.73% increase from the previous day's closing price.
A total volume of 614,100 shares were traded at the close of the day’s session.
In the last one week, shares of Supernus Pharmaceuticals Inc have slipped by -0.53%.
Supernus Pharmaceuticals Inc's Key Ratios
Supernus Pharmaceuticals Inc has a market cap of $1.83 billion, indicating a price to book ratio of 2.2332 and a price to sales ratio of 2.9106.
In the last 12-months Supernus Pharmaceuticals Inc’s revenue was $668.50 million with a gross profit of $580.02 million and an EBITDA of $131.29 million. The EBITDA ratio measures Supernus Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Supernus Pharmaceuticals Inc’s operating margin was 6.96% while its return on assets stood at 1.69% with a return of equity of 5.98%.
In Q1, Supernus Pharmaceuticals Inc’s quarterly earnings growth was a negative -33.8% while revenue growth was a positive 0.8%.
Supernus Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 20.1613
- Trailing PE
- 37.2556
- PEG
- 1.47
Its diluted EPS in the last 12-months stands at $0.9 per share while it has a forward price to earnings multiple of 20.1613 and a PEG multiple of 1.47. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Supernus Pharmaceuticals Inc’s profitability.
Supernus Pharmaceuticals Inc stock is trading at a EV to sales ratio of 2.9697 and a EV to EBITDA ratio of 16.8025. Its price to sales ratio in the trailing 12-months stood at 2.9106.
Supernus Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.79 billion
- Total Liabilities
- $731.55 million
- Operating Cash Flow
- $239.78 million
- Capital Expenditure
- $278000
- Dividend Payout Ratio
- 0%
Supernus Pharmaceuticals Inc ended 2023 with $1.79 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.79 billion while shareholder equity stood at $912.15 million.
Supernus Pharmaceuticals Inc ended 2023 with $49.67 million in deferred long-term liabilities, $731.55 million in other current liabilities, 54000.00 in common stock, $498.19 million in retained earnings and $117.02 million in goodwill. Its cash balance stood at $58.44 million and cash and short-term investments were $228.57 million. The company’s total short-term debt was $480,863,000 while long-term debt stood at $0.
Supernus Pharmaceuticals Inc’s total current assets stands at $883.34 million while long-term investments were $54.16 million and short-term investments were $170.13 million. Its net receivables were $143.57 million compared to accounts payable of $95.35 million and inventory worth $91.15 million.
In 2023, Supernus Pharmaceuticals Inc's operating cash flow was $239.78 million while its capital expenditure stood at $278000.
Comparatively, Supernus Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $33.53
- 52-Week High
- $42.09
- 52-Week Low
- $25.8
- Analyst Target Price
- $43
Supernus Pharmaceuticals Inc stock is currently trading at $33.53 per share. It touched a 52-week high of $42.09 and a 52-week low of $42.09. Analysts tracking the stock have a 12-month average target price of $43.
Its 50-day moving average was $35.9 and 200-day moving average was $36.06 The short ratio stood at 13.07 indicating a short percent outstanding of 0%.
Around 494% of the company’s stock are held by insiders while 10451.9% are held by institutions.
Frequently Asked Questions About Supernus Pharmaceuticals Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company’s commercial products also comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson’s Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson’s disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a product candidate in Phase II clinical trials for treating resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.